Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice - PubMed (original) (raw)
Review
. 2013 Aug;39(5):498-506.
doi: 10.1016/j.ctrv.2012.09.006. Epub 2012 Oct 18.
Affiliations
- PMID: 23084098
- DOI: 10.1016/j.ctrv.2012.09.006
Review
Treatment of patients with small-cell lung cancer: from meta-analyses to clinical practice
Antonio Rossi et al. Cancer Treat Rev. 2013 Aug.
Abstract
Despite decades of intensive biological and clinical research, there still remains a substantial lack of consensus regarding the appropriate therapeutic management of patients with small-cell lung cancer (SCLC). Many randomized studies have been performed to identify the most effective treatment strategy, the best agents or treatment duration, the most appropriate dose and timing of radiotherapy and thus providing more reliable evidence for clinical practice. Unfortunately most of these trials reported contrasting results, and in several meta-analyses have been performed, with the intent to clarify the strategic approach for each issue. This review focuses on the contribution of the main meta-analyses in defining the standard approaches in the treatment of SCLC, discussing their real value and influence on every-day decision making. According to the results of available meta-analyses, platinum-based chemotherapy should be considered the standard of care for the treatment of SCLC. Cisplatin and carboplatin have shown similar efficacy, and the choice of the platinum compound for the treatment of patients with extensive stage SCLC should consider the expected toxicity profile, organ function, performance status, and comorbidities. Thoracic radiotherapy, administered early and in combination with chemotherapy, improves long-term results, although with higher toxicity. Prophylactic cranial irradiation in patients with limited disease obtaining response after induction treatment is a standard of care. Maintenance treatment, intensified chemotherapy and use of growth factors have not proven significant efficacy. Topotecan is effective as second-line treatment, although evidence on clinical benefit for patients relapsed after first-line is limited.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
- [Evidence based chemotherapy for lung cancer].
Watanabe H, Saijo N. Watanabe H, et al. Gan To Kagaku Ryoho. 2000 Jan;27(1):30-43. Gan To Kagaku Ryoho. 2000. PMID: 10660731 Japanese. - [Recent issue in the treatment of small-cell lung cancer].
Ueoka H, Hiraki S. Ueoka H, et al. Gan To Kagaku Ryoho. 1998 Sep;25(11):1665-70. Gan To Kagaku Ryoho. 1998. PMID: 9757190 Review. Japanese. - Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.
Ariyoshi Y, Fukuoka M, Furuse K, Saijo N, Ikegami H, Nishiwaki Y, Tamura T, Shimoyama M, Suemasu K. Ariyoshi Y, et al. Jpn J Clin Oncol. 1994 Oct;24(5):275-81. Jpn J Clin Oncol. 1994. PMID: 7967106 Clinical Trial. - Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
Brugger W, Frommhold H, Pressler K, Mertelsmann R, Kanz L. Brugger W, et al. Semin Oncol. 1995 Feb;22(1 Suppl 2):3-8. Semin Oncol. 1995. PMID: 7531368 Clinical Trial. - [Therapeutic strategy for small cell lung cancer].
Fukuoka M. Fukuoka M. Nihon Geka Gakkai Zasshi. 1997 Jan;98(1):46-52. Nihon Geka Gakkai Zasshi. 1997. PMID: 9046518 Review. Japanese.
Cited by
- Development of a novel nomogram for patients with SCLC and comparison with other models.
Hou Q, Liang Y, Yao N, Liu J, Cao X, Zhang S, Wei L, Sun B, Feng P, Zhang W, Cao J. Hou Q, et al. BMC Cancer. 2024 Oct 10;24(1):1257. doi: 10.1186/s12885-024-12791-9. BMC Cancer. 2024. PMID: 39390375 Free PMC article. - The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics.
Trillo Aliaga P, Del Signore E, Fuorivia V, Spitaleri G, Asnaghi R, Attili I, Corvaja C, Carnevale Schianca A, Passaro A, de Marinis F. Trillo Aliaga P, et al. Genes (Basel). 2024 May 27;15(6):701. doi: 10.3390/genes15060701. Genes (Basel). 2024. PMID: 38927637 Free PMC article. Review. - A novel analytical framework for risk stratification of real-world data using machine learning: A small cell lung cancer study.
Marzano L, Darwich AS, Tendler S, Dan A, Lewensohn R, De Petris L, Raghothama J, Meijer S. Marzano L, et al. Clin Transl Sci. 2022 Oct;15(10):2437-2447. doi: 10.1111/cts.13371. Epub 2022 Jul 29. Clin Transl Sci. 2022. PMID: 35856401 Free PMC article. - Association of PTEN Gene SNPs rs2299939 With PFS in Patients With Small Cell Lung Cancer Treated With Early Radiotherapy.
Wang C, Yang D, Zhang X, Zhang X, Yang L, Wang P, Zhou W, Li H, Li Y, Nie H, Li Y. Wang C, et al. Front Genet. 2020 Apr 23;11:298. doi: 10.3389/fgene.2020.00298. eCollection 2020. Front Genet. 2020. PMID: 32391045 Free PMC article. - Oridonin inhibits the migration and epithelial-to-mesenchymal transition of small cell lung cancer cells by suppressing FAK-ERK1/2 signalling pathway.
Xu L, Bi Y, Xu Y, Zhang Z, Xu W, Zhang S, Chen J. Xu L, et al. J Cell Mol Med. 2020 Apr;24(8):4480-4493. doi: 10.1111/jcmm.15106. Epub 2020 Mar 13. J Cell Mol Med. 2020. PMID: 32168416 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical